These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32361064)
1. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. Yun F; Cheng C; Ullah S; Yuan Q Eur J Med Chem; 2020 Jul; 198():112322. PubMed ID: 32361064 [TBL] [Abstract][Full Text] [Related]
2. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. Cheng C; Yun F; Ullah S; Yuan Q Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336 [TBL] [Abstract][Full Text] [Related]
3. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. Xie R; Li Y; Tang P; Yuan Q Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. Cheng C; Yun F; He J; Ullah S; Yuan Q Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060 [TBL] [Abstract][Full Text] [Related]
6. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806 [TBL] [Abstract][Full Text] [Related]
7. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors. Elgazwy AS; Ismail NS; Elzahabi HS Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors. Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540 [TBL] [Abstract][Full Text] [Related]
9. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
10. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies. Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025 [TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity. El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512 [TBL] [Abstract][Full Text] [Related]
13. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Mao PT; He WB; Mai X; Feng LH; Li N; Liao YJ; Zhu CS; Li J; Chen T; Liu SH; Zhang QM; He L Bioorg Med Chem; 2022 Feb; 56():116599. PubMed ID: 35041998 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. Saidahmatov A; Li J; Xu S; Hu X; Gao X; Kan W; Gao L; Li C; Shi Y; Sheng L; Wang P; Zhou Y; Liang X; Li J; Liu H J Med Chem; 2024 Sep; 67(17):15220-15245. PubMed ID: 39178382 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity. Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer. Cui H; Huang J; Lei Y; Chen Q; Hu Z; Niu J; Wei R; Yang K; Li H; Lu T; Zhu Y; Huang Y Eur J Med Chem; 2022 Feb; 229():114082. PubMed ID: 34995925 [TBL] [Abstract][Full Text] [Related]